Seth A Climans1,2, Eva Grunfeld1, Warren P Mason3,4, Kelvin K W Chan1. 1. Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada. 2. Department of Oncology, Western University, London, Ontario, Canada. 3. Department of Medicine, Division of Neurology, University of Toronto, Toronto, Ontario, Canada. 4. Department of Medical Oncology and Hematology, University of Toronto, Toronto, Ontario, Canada.
Abstract
BACKGROUND: Malignant gliomas are treated with temozolomide chemoradiotherapy. Because pneumocystis pneumonia (PCP) can occur in patients receiving temozolomide, the product monograph recommends PCP prophylaxis during temozolomide chemoradiotherapy. Not all neuro-oncologists follow these recommendations, though. METHODS: We performed a population-based retrospective cohort study of glioma patients undergoing temozolomide chemoradiotherapy 2005 to 2019 in Ontario, Canada. A propensity score model was used to predict the use of PCP prophylaxis. We compared the risk of PCP within 90 days of starting radiotherapy with versus without PCP prophylaxis using inverse probability of treatment weighting (IPTW). We also examined overall survival, hospitalizations, and myelosuppression. RESULTS: There were 3,225 patients included in the cohort (648 received antibiotics and 2,434 did not). Only 18 patients developed PCP within 90 days of therapy. The IPTW-adjusted absolute risk reduction in PCP with antibiotics was 0.0035 (95% CI, -0.0013 to 0.0083), number needed to treat: 288. Neither overall survival nor hospitalization count differed between the groups. The number needed to harm by causing grade 3/4 neutropenia was 39. CONCLUSIONS: In regions (like Ontario) where PCP is rare, routine PCP prophylaxis with trimethoprim-sulfamethoxazole should not be offered, since the harms may outweigh the benefits.
BACKGROUND: Malignant gliomas are treated with temozolomide chemoradiotherapy. Because pneumocystis pneumonia (PCP) can occur in patients receiving temozolomide, the product monograph recommends PCP prophylaxis during temozolomide chemoradiotherapy. Not all neuro-oncologists follow these recommendations, though. METHODS: We performed a population-based retrospective cohort study of glioma patients undergoing temozolomide chemoradiotherapy 2005 to 2019 in Ontario, Canada. A propensity score model was used to predict the use of PCP prophylaxis. We compared the risk of PCP within 90 days of starting radiotherapy with versus without PCP prophylaxis using inverse probability of treatment weighting (IPTW). We also examined overall survival, hospitalizations, and myelosuppression. RESULTS: There were 3,225 patients included in the cohort (648 received antibiotics and 2,434 did not). Only 18 patients developed PCP within 90 days of therapy. The IPTW-adjusted absolute risk reduction in PCP with antibiotics was 0.0035 (95% CI, -0.0013 to 0.0083), number needed to treat: 288. Neither overall survival nor hospitalization count differed between the groups. The number needed to harm by causing grade 3/4 neutropenia was 39. CONCLUSIONS: In regions (like Ontario) where PCP is rare, routine PCP prophylaxis with trimethoprim-sulfamethoxazole should not be offered, since the harms may outweigh the benefits.
Authors: N Mittmann; J M Porter; J Rangrej; S J Seung; N Liu; R Saskin; M C Cheung; N B Leighl; J S Hoch; M Trudeau; W K Evans; K N Dainty; C DeAngelis; C C Earle Journal: Curr Oncol Date: 2014-12 Impact factor: 3.677
Authors: James Y Chen; Elizabeth Hovey; Mark Rosenthal; Ann Livingstone; John Simes Journal: Asia Pac J Clin Oncol Date: 2013-05-29 Impact factor: 2.601
Authors: Filip Y De Vos; Johanna M Gijtenbeek; Chantal P Bleeker-Rovers; Carla M van Herpen Journal: Crit Rev Oncol Hematol Date: 2012-08-25 Impact factor: 6.312